Skip to search boxSkip to navigationSkip to main content

A heavy metal baseline score predicts outcome in acute myeloid leukemia

  • Maro Ohanian(corresponding author)
    ,
  • Philippe Telouk
    ,
  • Steven Kornblau
    ,
  • Francis Albarede
    ,
  • Peter Ruvolo
    ,
  • Rebecca S.S. Tidwell
*Corresponding author for this work
  • University of Texas MD Anderson Cancer Center
    ,
  • École normale supérieure de Lyon
    ,
  • Hospices civils de Lyon
    ,
  • ,
  • University of Texas Health Science Center at Houston
Scholary Output:
Contribution to journal
Article
Research
Peer-review

Open access

Sustainable Development Goals

  • SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well

Abstract

<p>Despite abundant epidemiological data linking metals to leukemia and other cancers, baseline values of toxic and essential metals in patients with leukemia and the clinical impact of these metals remain unknown. Thus, we sought to quantify metal values in untreated patients with acute myeloid leukemia (AML) and controls and determine the impact of metal values on AML patients' survival. Serum samples from patients with untreated AML and controls at Hospices Civils de Lyon were analyzed and compared for trace metals and copper isotopic abundance ratios with inductively coupled plasma mass spectrometry. Survival analysis was performed as a function of metal values, and a multi-metal score was developed for patients with AML. Serum samples were collected from 67 patients with untreated AML and 94 controls. Most patients had intermediate-risk cytogenetics (63.1%) without FLT3 internal tandem duplication mutations (75.6%) or NPM1 mutations (68.1%). Most metal values differed significantly between AML and control groups. Patients with lower magnesium and higher cadmium values had the worst survival rates, with only 36% surviving at 6 months (P =.001). The adverse prognostic effect of this combination was maintained on multivariate analysis. Based on this, we developed a novel metal score, which accounts for multiple relative abnormalities in the values of five toxic and five essential metals. Patients with a higher metal score had significantly worse survival, which was maintained on multivariate analysis (P =.03). This baseline metal scoring system was also prognostic when we applied it to a separate population of front-line AML patients.</p>

Publication Information

Output type

Scholary Output:
Contribution to journal
Article
Research
Peer-review

Original language

English (US)

Pages from-to (Number of pages)

Pages 422-434 (13 pages)

Journal (Volume, Issue Number)

American Journal of Hematology (Volume 95, Issue 4)

Publication milestones

  • Accepted/In press - 2020
  • Published - 04/2020

Publication status

Published - 04/2020

ISSN

0361-8609

Publication IDs

  • Scopus: 85082312825
  • PubMed: 31944361
  • ORCID: /0000-0002-8636-1071/work/90810461

Publication metrics

Metrics

SciVal
FWCI
0.21
SciVal
Author count
12
SciVal
citations
1
SciVal
Paper percentile
68
Fractional count
1
Fractional count
0.08
Fractional count
11
Fractional count
0.92
Fractional count
1
Fractional count
1
Scopus
citations

PlumX, opens in new tab

Captures
43
Citation count
22
Mentions
1

Funding Details

Partial funding for this project was provided by the following: Southwest Center for Occupational and Environmental Health, a National Institute for Occupational Safety and Health (NIOSH) Education and Research Center, and awardee of Grant No. 5T42OH008421 from NIOSH and the Centers for Disease Control and Prevention; the National Institutes of Health/National Cancer Institute Cancer Center Support Grant P30CA016672 to MD Anderson Cancer Center (Biostatistics Resource Group); the University of Texas MD Anderson Cancer Center Duncan Family Institute for Cancer Prevention and Risk Assessment; the Leukemia Texas Foundation; Ladies Leukemia League; the Khalifa Foundation Gift; the Global Academic Programs Sister Institute Network Fund; a Gillson‐Longenbaugh Foundation Grant; the Max Cure Foundation; and the Cancer Recovery Foundation; INSU (Institut National des Sciences de l'Univers); CLARA (Cancéropôle Lyon Auvergne Rhône Alpes); MD Anderson Cancer Center Leukemia SPORE CA100632. Funding information
FundersFunding numbers
Cancer Recovery Foundation
-
Cancéropôle Lyon Auvergne Rhône Alpes
CA100632
Gillson‐Longenbaugh Foundation
-
Global Academic Programs Sister Institute Network Fund
-
Khalifa Foundation Gift
-
Leukemia Texas Foundation
-
Max Cure Foundation
-
NIH
-
CDC
-
NCI
P30CA016672
NIOSH
5T42OH008421
LLL
-
University of Texas MD Anderson Cancer Center
-
SWCOEH
-
INSU,CNRS
-